<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00466089</url>
  </required_header>
  <id_info>
    <org_study_id>MO19182</org_study_id>
    <nct_id>NCT00466089</nct_id>
  </id_info>
  <brief_title>Study of 3D Radiotherapy With or Without Erlotinib (Tarceva®) in Patients With Localized Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase II Randomized Trial of 3D Radiotherapy Versus the Combination of 3D Radiotherapy and Erlotinib (Tarceva®) in Patients With Localized-Unresectable Non-Small Cell Lung Cancer Non Susceptible for Chemotherapy Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital of Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr. Enrique Martínez López</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital of Navarra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II, multicenter, randomized trial of 3D Radiotherapy versus 3D Radiotherapy and
      erlotinib (Tarceva®) in patients with localized-unresectable (IA-IIIB) non-small cell lung
      cancer non susceptible for chemotherapy treatment, to compare safety and toxicity profile,
      and the progression-free survival in both arms of treatment (3D Radiotherapy versus 3D
      Radiotherapy + erlotinib) in patients who have not received previous chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2006</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determinate the viability and toxicity profile of Erlotinib + 3D Radiotherapy treatment (% of patients presenting toxicity 3-4 during the treatment).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The progression-free survival.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year survival.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate, according to RECIST criteria.</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RT + Tarceva</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>RT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib (Tarceva®)</intervention_name>
    <description>Erlotinib (Tarceva®), 150mg/day p.o during 6 months.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent prior to any specific procedure of the protocol.

          -  Histologically confirmed diagnosis of non small cell lung cancer.

          -  Unresectable (IA-IIIB) non-small cell lung cancer.

          -  Patients non susceptible for chemotherapy treatment

          -  Measurable disease according to RECIST criteria

          -  Age &gt; 18 years.

          -  ECOG performance status &lt; 2.

          -  Adequate bone marrow, hepatic, renal and respiratory function.

          -  Patients capable of following an adequate therapeutic compliance and accessible for a
             correct follow-up.

          -  Women at a fertile age must have a negative serum or urine pregnancy test within the 7
             days prior to the beginning of the treatment.

          -  Patients of both genders at a fertile age, including those women having their last
             menstruation within the two previous years, must follow effective contraceptive
             measures.

        Exclusion Criteria:

          -  Prior chemotherapy or radiotherapy.

          -  History of other curatively treated malignancy and no evidence of disease within the
             past 5 years except squamous cell skin cancer, or resected cervix carcinoma.

          -  Pregnant or lactating women.

          -  Any other severe disease or clinical conditions, as, but not only:

               1. Unstable cardiopathy despite treatment, myocardial infarction within the 6 months
                  before entering the study

               2. Uncontrolled active infection

               3. Uncontrolled peptic ulcer, unstable diabetes mellitus or any other
                  contraindication for treatment with corticosteroids.

               4. Autoimmune diseases.

          -  Concomitant treatment with any other antineoplastic therapy.

          -  Prior experimental pharmacological agent within the 3 weeks prior to the inclusion of
             the study.

          -  Prior treatment with EGFR targeted therapies.

          -  Erlotinib known hypersensibility.

          -  Any radiotherapy treatment contraindication.

          -  History of significant neurological or psychiatric disorders, including epileptic
             seizures.

          -  Any significant ophthalmologic impairment of the eye surface (Use of contact lenses is
             not recommended)

          -  Inability to take oral medication and surgical procedures affecting the absorption or
             implying intravenous or parenteral feeding.

          -  Any other underlying severe process affecting the ability to take part in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique Martínez, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Mª Perez Casas, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación Jimenez Diaz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alejandro De la Torre, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Puerta de Hierro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesc Casas, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínic i Provincial de Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nuria Viñolas, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínic i Provincial de Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julian Minguez, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Donostia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Enrique Martinez, Dr.</last_name>
    <phone>00 34 848 42 22 22</phone>
    <phone_ext>2161</phone_ext>
    <email>enrique.martinez.lopez@cfnavarra.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Enrique Martinez, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nuria Viñolas, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesc Casas, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <zip>28035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alejandro De la Torre, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundación Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ana Mª Perez Casas, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Donostia</name>
      <address>
        <city>San Sebastian</city>
        <zip>20080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Julian Minguez, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2007</study_first_submitted>
  <study_first_submitted_qc>April 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2007</study_first_posted>
  <last_update_submitted>January 9, 2008</last_update_submitted>
  <last_update_submitted_qc>January 9, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Enrique Martínez López</name_title>
    <organization>Dr. Enrique Martínez López</organization>
  </responsible_party>
  <keyword>NSCLC, lung cancer</keyword>
  <keyword>Patients with localized-unresectable (IA-IIIB) non-small cell lung cancer non susceptible for chemotherapy treatment.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

